Friday, December 24, 2021 5:25:33 AM
I agree with you lrdpdx77,
Im also invested in other biotechs and the trend, unfortunately, at present in the markets is that positive read outs are no longer a green light for whales to jump in. Heck if anything its a green light to short the biotech stock after positive TLD.
Im afraid that the days for huge gains after positive TLD are for now over. Im convinced that the DCVAX L publication we are waiting for will show that DCVAX L will be the new SOC for true GBM. What I am however not so convinced about anymore is if that will set the SP to a level that most investors want it to jump to. The market yells at listed companies: SHOW ME THE MONEY. DD showed some sort of survey on Twitter of ¾ of people thinking NWBO SP will be above $20 at the end of Q1 after publication, I hope it will be so but Im afraid many will be disappointed if they have this as a price target.
We need uplisting, revenue and approval for a MC of > $ 20 billion.
Im also invested in other biotechs and the trend, unfortunately, at present in the markets is that positive read outs are no longer a green light for whales to jump in. Heck if anything its a green light to short the biotech stock after positive TLD.
Im afraid that the days for huge gains after positive TLD are for now over. Im convinced that the DCVAX L publication we are waiting for will show that DCVAX L will be the new SOC for true GBM. What I am however not so convinced about anymore is if that will set the SP to a level that most investors want it to jump to. The market yells at listed companies: SHOW ME THE MONEY. DD showed some sort of survey on Twitter of ¾ of people thinking NWBO SP will be above $20 at the end of Q1 after publication, I hope it will be so but Im afraid many will be disappointed if they have this as a price target.
We need uplisting, revenue and approval for a MC of > $ 20 billion.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
